All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
GvHD Hub EBMT Symposium 2024: 30 years of ECP in GvHD: Recommendations for the treatment of cGvHD
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
On April 14, 2024, the GvHD Hub held a symposium at the 50th European Society for Bone and Marrow Transplantation (EBMT) Annual Meeting on the role of extracorporeal photopheresis (ECP) in the management of chronic graft-versus-host disease (cGvHD).
Here, we share the presentation by Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne Université, Paris, FR, which explored a brief history of ECP, outlined the allogeneic hematopoietic stem cell transplantation (Figure 1) and ECP procedures (Figure 2), and also included two cGvHD patient case studies.
Figure 1. The allo-HSCT procedure*
aGvHD, acute graft-versus-host disease; allo-HSCT, allogeneic hematopoietic stem cell transplantation; cGvHD, chronic graft-versus-host disease; CMV, cytomegalovirus; GvHD, graft-versus-host disease.
*Adapted from Mohty, et al.2 Created with Biorender.com.
Figure 2. What is ECP?
ECP, extracorporeal photopheresis; GvHD, graft-versus-host disease; UVA, ultraviolet A.
*Adapted from Knobler R, et al.3 Created with Biorender.com
This symposium closed with a panel Q&A session with live audience participation, where our panelists shared their perspectives on the impact of ECP on the GvHD treatment landscape and the importance of early intervention in GvHD treatment.
Symposium | Q&A | Impact of ECP on the GvHD treatment landscape
This independent educational activity was supported by Mallinckrodt Pharmaceuticals. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.
GvHD Hub EBMT Symposium 2024: 30 years of ECP in GvHD: Recommendations for the treatment of cGvHD
Subscribe to get the best content related to GvHD delivered to your inbox